ArticleScientific reports2021
Benefits and risks of antiplatelet medication in hemodynamically stable adult moyamoya disease.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Clinical and radiological course of asymptomatic and hemodynamically stable moyamoya disease: a systematic review and meta-analysis.Frontiers in neurology · 2025Pooled it
- Antiplatelet Treatment in Moyamoya Disease: A Systematic Review.Cerebrovascular diseases extra · 2024Pooled it
- Benefits and risks of antiplatelet therapy for moyamoya disease: a systematic review and meta-analysis.Frontiers in neurology · 2023Pooled it
- Vessel wall imaging in adult moyamoya disease with presumed acute in situ thrombotic occlusion: illustrative cases.Journal of neurosurgery. Case lessons · 2026Article
- Effects of antiplatelet therapy on reducing stroke risk in patients with moyamoya disease: the role of postcontrast MR vessel wall imaging.European radiology · 2025Article
- Diagnosis and management of adult Moyamoya angiopathy: An overview of guideline recommendations and identification of future research directions.International journal of stroke : official journal of the International Stroke Society · 2025Review
- Review
- Article
- Letters to editor regarding the article "Outcomes of surgical revascularization for pediatric moyamoya disease and syndrome".Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025Article
- Reinforcement of Transdural Angiogenesis: A Novel Approach to Treating Ischemic Stroke With Cerebral Perfusion Impairment.Journal of stroke · 2025Review
- Medical Management of Adult Moyamoya Disease: A Review and Relevant Cases With Ischemic Events.Journal of stroke · 2025Review
- Comparing Outcomes of Moyamoya Disease and Moyamoya Syndrome in a Real-World Scenario: A Cohort Study.CNS neuroscience & therapeutics · 2024Article
- Is medical management useful in Moyamoya disease?World journal of clinical cases · 2024Article
- A Rare Case of Moyamoya Disease in a Hispanic Woman: Unveiling Non-Asian Ethnicity and Atypical Risk Factors.The American journal of case reports · 2023Review
- European Stroke Organisation (ESO) Guidelines on Moyamoya angiopathy Endorsed by Vascular European Reference Network (VASCERN).European stroke journal · 2023Article
- Current Understanding of Moyamoya Disease (MMD) and Associated Neuropsychiatric Outcomes.Neuropsychiatric disease and treatment · 2023Review
- Safety and efficacy of aspirin after combined cerebral revascularization for ischemic moyamoya disease: A prospective study.Frontiers in surgery · 2023Article
- Microembolic signals and antiplatelet therapy in Moyamoya angiopathy.Journal of neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Revascularization surgery is considered a standard treatment for preventing additional stroke in symptomatic moyamoya disease (MMD). In hemodynamically stable, and asymptomatic or mildly symptomatic patients, however, the treatment strategy is controversial because of the obscure natural course of them. The authors analyzed the benefits and risks of antiplatelet medication in those patients. Medical data were retrospectively reviewed in 439 hemispheres of 243 patients with stable hemodynamic status. Overall, 121 patients (49.8%) with 222 studied hemispheres (50.6%) took antiplatelet medication. Symptomatic cerebral infarction and hemorrhage occurred in 10 (2.3%) and 30 (6.8%) hemispheres, over a mean follow-up of 62.0 ± 43.4 months (range 6-218 months). The use of antiplatelet agents was statistically insignificant in terms of symptomatic infarction, hemorrhage and improvement of ischemic symptoms. In subgroup analyses within the antiplatelet group according to drug potency and duration of medication, a longer duration of antiplatelet medication significantly improved ischemic symptoms (adjusted OR 1.02; 95% CI 1.01-1.03; p = 0.006). Antiplatelet medication failed to prevent symptomatic cerebral infarction or improve ischemic symptoms. However, antiplatelet therapy did not increase the risk of cerebral hemorrhage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.